Market Snapshot
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors
The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.

MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space
The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.

SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.

Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains
While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.

New Products Shake Up Overlooked Bipolar Disorder Market
The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.

A Deep Dive Into The Game-Changing Drugs For Skin Diseases
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off
Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.

Wet AMD Market Snapshot: A High-Growth Market Poised For Change
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

UC Market Gets Increasingly Crowded – But High Unmet Need Remains
Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.

The Extraordinary But Uncertain Growth Of The COVID-19 Market
The value of the COVID-19 market reached more than $8bn in the first quarter, fuelled by mRNA-based vaccines, but the future growth of the sector depends on the rather unpredictable course of the pandemic, and the response of healthcare providers and countries.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.